Johnson & Johnson Proposes $5.5 Billion Talc Settlement to End a Decade of Lawsuits

Johnson & Johnson has proposed a $5.5 billion settlement to resolve the vast majority of lawsuits alleging that its talc-based baby powder caused cancer — a bid to close one of the longest-running legal sagas in corporate America.

Announced July 28, 2026, the proposal would cover roughly 69,000 claims consolidated in federal court in New Jersey, plus related state cases — about 99.75% of remaining talc claims. The plaintiffs, largely women, allege that the products were contaminated with asbestos and contributed to ovarian cancer.

What the allegation actually is

The claim concerns contamination rather than talc itself, and the distinction matters for how the science is argued.

Talc and asbestos are both naturally occurring silicate minerals, and they can form in the same geological deposits. Talc mined from such a deposit can contain asbestos fibres unless the source is carefully selected and the product tested.

Asbestos is an established human carcinogen with no serious scientific dispute about its capacity to cause cancer. So the plaintiffs’ case does not require proving that talc causes cancer — it requires proving that these particular products contained asbestos and that exposure caused disease in individual claimants.

Studies of talc use and ovarian cancer have produced inconsistent results, which is a significant part of why this litigation has persisted through years of contested trials rather than resolving.

The terms

The settlement is conditioned on at least 95% of remaining claimants agreeing to participate. J&J would make an initial payment of no more than $3 billion next year, with no further payments due until 2028.

The participation threshold is the essential mechanism. A settlement resolving most claims but leaving thousands outside it would not achieve finality, and the company would continue facing individual trials with the associated cost and unpredictability.

Requiring 95% means the deal either closes the matter substantially or does not take effect — and it creates pressure among claimants to accept, since holdouts risk the settlement failing for everyone.

The payment schedule is also favourable in present-value terms. Deferring the balance to 2028 makes $5.5 billion nominally cost less than $5.5 billion today.

The company’s position

J&J continues to deny that its talc products pose any cancer risk, framing the settlement as a way to end costly, distracting litigation rather than an admission.

Settling without admitting liability is standard, and it is not merely a formality: an admission would have consequences for remaining claims, for insurance coverage and for regulatory exposure.

It is also a reflection of how mass tort economics work. Even a defendant confident of winning most trials faces enormous aggregate cost and the risk of occasional very large verdicts, so settling can be rational independently of the merits.

The bankruptcy attempts

The company has fought these claims — the first filed in 2016 — through years of trials and two failed attempts to route the liability through bankruptcy.

Those attempts used a manoeuvre in which liabilities are moved into a newly created subsidiary which then files for bankruptcy, while the profitable business continues unaffected. The intent is to force all claims into a single bankruptcy proceeding, where they are resolved collectively rather than through individual trials.

Courts rejected the approach, principally on the ground that a solvent company cannot use bankruptcy protection it does not need. The failure of that route is much of why an ordinary settlement is now on the table.

Why it matters

Beyond the headline number, the deal signals a strategic reset: resolving legacy consumer-health liabilities lets J&J focus on pharmaceuticals and medtech.

Why the product was withdrawn before the litigation ended

J&J stopped selling talc-based baby powder in North America in 2020 and globally thereafter, replacing it with a cornstarch formulation — while continuing to maintain the product was safe.

The two positions are consistent commercially even if they read oddly. Sales of the product had fallen substantially, partly through the publicity the litigation generated, and a low-margin consumer item generating enormous legal exposure is not worth defending in the market regardless of its merits.

Cornstarch was already the alternative most competitors used, so the reformulation was straightforward and cost little in capability.

What withdrawal does not do is limit liability. Claims concern exposure over decades, and ovarian cancer develops long after the exposure alleged to have caused it — so the claimant population was already fixed by past sales, and new cases will continue to be filed for years.

That latency is a general feature of this kind of litigation and part of why it runs so long. It also explains the structure of the settlement: resolving 99.75% of claims now is an attempt to draw a line under a liability whose natural endpoint is decades away.

For claimants, it offers a faster route to compensation than years more of litigation. The allegations remain contested, and the settlement still needs sufficient claimant buy-in to take effect. Business news, not legal or medical advice.